Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
BORTDEXAPOMA
- Cancer Type
- Hematologic, Multiple Myeloma
- Intent
-
Palliative
- Regimen Category
-
Evidence-informed
- Funding Program
-
ODB - General Benefit dexamethasone Exceptional Access Program pomalidomide - In combination with bortezomib and dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma, based on criteria
- Drugs Used
- bortezomib , dexamethasone , pomalidomide
Regimen Monograph
Mar 2026
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: July 21, 2026
